NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 3 FDA
NCT02077881 2026-04-03Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerLumos PharmaPhase 1/2 Completed157 enrolled 18 charts
NCT05014776 2026-02-24Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Active not recruiting17 enrolled 8 charts
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 3 FDA